Literature DB >> 9696366

Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy?

T Siegal1.   

Abstract

Malignant subarachnoid deposits complicate both primary central nervous system (CNS) tumors and systemic neoplasms. Although the pathophysiology of symptoms and signs can not be separated by the category of primary tumors that seeds the leptomeninges, the approach to therapy is not similar in primary CNS tumors and in systemic neoplasms. Standard therapy for subarachnoid seeding in primary CNS tumors include conventional or high doses of systemic chemotherapy with various combinations of radiotherapy given either to limited fields or to the whole neuroaxis. Direct administration of chemotherapy to the CSF is not being used. In contrast, whenever a systemic tumor seeds the subarachnoid space the standard approach includes intensive intra-CSF chemotherapy, radiotherapy to limited or extended CNS fields and various combinations of systemic chemotherapy. The published experience with the conventional therapy is reviewed and is critically analyzed. Evidence indicating that high dose systemic chemotherapy can replace intra-CSF treatment in some subgroups are also reviewed and the rationale for this approach is specified. Recent experience in which intra-CSF therapy was prospectively eliminated from the treatment protocol of leptomeningeal metastases of solid tumors reveals that the response rate and survival are similar to those obtained by protocols that differed only by the inclusion of intra-CSF chemotherapy. Patients who were treated by radiotherapy alone combined with systemic chemotherapy but without the intra-CSF therapy were spared the high rate of early and delayed complications directly related to intra-CSF therapy. Still, treatment outcome did not differ. Therefore, future research efforts and prospective clinical trials should investigate the best chemotherapeutic schedules and their sequencing with radiotherapy or with more intensive complementary systemic chemotherapy schemes. Newly designed drugs with long circulation time and improved CNS penetration may serve for this purpose.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696366     DOI: 10.1023/a:1005999228846

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

2.  Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases.

Authors:  M C Chamberlain; P A Kormanik
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

3.  A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.

Authors:  R N Hitchins; D R Bell; R L Woods; J A Levi
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

4.  The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.

Authors:  E Morra; M Lazzarino; E Brusamolino; G Pagnucco; C Castagnola; P Bernasconi; E Orlandi; A Corso; A Santagostino; C Bernasconi
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

5.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

6.  Successful chemotherapy of recurrent intracranial germinoma with spinal metastases.

Authors:  T Siegal; M R Pfeffer; R Catane; A Sulkes; M J Gomori; Z Fuks
Journal:  Neurology       Date:  1983-05       Impact factor: 9.910

7.  Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant.

Authors:  G C Jayson; A Howell; M Harris; G Morgenstern; J Chang; W D Ryder
Journal:  Cancer       Date:  1994-12-15       Impact factor: 6.860

8.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.

Authors:  K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

9.  Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases--a Southwest Oncology Group study.

Authors:  W T Sause; J Crowley; H J Eyre; S E Rivkin; R P Pugh; J M Quagliana; S A Taylor; B Molnar
Journal:  J Neurooncol       Date:  1988-09       Impact factor: 4.130

10.  Central nervous system pharmacokinetics of high-dose cytosine arabinoside.

Authors:  J A Lopez; E Nassif; P Vannicola; J G Krikorian; R P Agarwal
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

View more
  19 in total

1.  Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy.

Authors:  Lisa R Rogers; Sandra E Remer; Sheela Tejwani
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

2.  Long-term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high-dose intravenous methotrexate.

Authors:  Carole Fakhry; Gopal Bajaj; Nafi Aygun; William Westra; Maura Gillison
Journal:  Head Neck       Date:  2010-08-24       Impact factor: 3.147

Review 3.  Metastatic neurologic complications of non-Hodgkin's lymphoma.

Authors:  Jeanine Grier; Tracy Batchelor
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

4.  Metastatic tumors of the nervous system.

Authors:  Sophie Taillibert; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 5.  Current options for the treatment of neoplastic meningitis.

Authors:  Ilkcan Cokgor; Allan H Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

6.  Leptomeningeal Neoplasms.

Authors:  Lauren E. Abrey
Journal:  Curr Treat Options Neurol       Date:  2002-03       Impact factor: 3.598

Review 7.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Authors:  Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2014-05-27       Impact factor: 12.300

Review 8.  Leptomeningeal metastases from solid malignancy: a review.

Authors:  Sophie Taillibert; Florence Laigle-Donadey; Catherine Chodkiewicz; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

9.  Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  CNS Oncol       Date:  2013-03

Review 10.  Toxicity of treatment for neoplastic meningitis.

Authors:  Tali Siegal
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.